Statutory Distinction Between New Drugs, Stem Cell Derived Products, and Autologous Procedures

Under Rule 2(1)(w)(v) of the New Drugs and Clinical Trial Rules, 2019, read alongside its statutory Explanation, stem cell derived products are deemed to permanently retain the classification of "new drugs," thereby remaining under the continuous regulatory and licensing scrutiny of the Central Licensing Authority for commercial usage. A biological preparation qualifies as a stem cell derived product only if it has undergone processing through substantial or more than minimal manipulation—such as ex-vivo alterations or expansions aimed at modifying cellular function—with the objective of differentiation, propagation, or cell line generation. In contrast, autologous stem cells harvested from a patient and reinjected during the same surgical intervention after undergoing minimal physical handling, such as rinsing, cleaning, sizing, or centrifugation, do not constitute stem cell derived products or new drugs under the Rules. Nevertheless, this procedural distinction does not exempt minimally manipulated autologous cells from rigorous scientific standards, nor does it grant medical practitioners open license to administer unproven autologous interventions as routine clinical care. (Yash Charitable Trust & Ors. Vs Union of India & Ors. | 2026 INSC 96).